Accelerating Biopharmaceutical Development with CE-MS - Summary - MDSpire
Feature

Accelerating Biopharmaceutical Development with CE-MS

Microfluidic CE-MS interfaces simplifies and streamlines biotherapeutic characterization to reduce turnaround times in bioanalytical labs

  • April 30, 2026

  • 7 min

Share

Biopharmaceutical developers face increasing demands to accelerate development timelines and enhance characterization of complex molecules. Utilizing LC-MS methods is common; however, they often require extensive optimization. As the biotherapeutics landscape evolves, microfluidic CE-MS interfaces, such as the PATsmart™ ZipChip®, offer an innovative alternative by providing rapid sample analysis and efficient data integration. Simon Krabbe from Servier discusses the challenges and benefits of adopting CE-MS for faster and more accurate biotherapeutic characterization.

Original Source(s)

Accelerating Biopharmaceutical Development with CE-MS

  • April 30, 2026

Related Content

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Differ

Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of tria...

Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...